ISNES, Belgium, March 25, 2019 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announced that its Executive Vice President, Investor Relations, Scott Powell, is scheduled to present at three conferences in March and April 2019.
During the conferences, Dr. Powell will outline Volition's business, clinical, regulatory and operational milestones, as well as the Company's recently announced clinical data and upcoming 2019 milestones.
Details of the conference presentations are as follows:
Conference: The MicroCap Spring Invitational
Date: Wednesday, March 27, 2019
Time: 6:00 p.m. - 9:00 p.m. EDT
Location: The Cornell Club, New York, NY
Conference: Sidoti & Company Spring 2019 Investor Conference
Date: Thursday, March 28, 2019
Location: The Marriott Marquis, New York, NY
Conference: Spring Investor Summit '19
Date: Monday, April 1, 2019
Time: 10:30 a.m. EDT
Location: J.W. Marriott Essex House New York, New York, NY
Persons attending any of the above-referenced conferences who would like to schedule a 1-on-1 meeting with Volition management during such conference may do so by contacting Joseph Green of Edison Advisors at JGreen@edisongroup.com or Scott Powell, Head of Investor Relations at firstname.lastname@example.org
We are also hosting a Capital Markets Day at the New York Stock Exchange on Tuesday April 9, 2019, with presentations from Scientific Advisory Board Member, Professor Axel Imhof of the Biomedical Center of the Ludwig-Maximilians University of Munich and from Associate Professor Heather Wilson-Robles of Texas A&M Veterinary School. We hope to provide further updates of results, ongoing projects and of plans for the potential new paths to revenues, most notably in lung cancer, Nu.Q Vet and in Nu.Q Capture.
For further details please contact email@example.com.
Volition is a multi-national life sciences company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases. Early diagnosis has the potential to not only prolong the life of patients, but also to improve their quality of life. The tests are based on the science of NucleosomicsTM, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present.
Volition's research and development activities are currently centered in Belgium, with additional offices in London, Texas and Singapore, as the company focuses on bringing its diagnostic products to market.
For more information about Volition, visit Volition's website (http://www.volitionrx.com) or connect with us via:
The contents found at Volition's website address, Twitter, LinkedIn, Facebook, and YouTube are not incorporated by reference into this document and should not be considered part of this document. The addresses for Volition's website, Twitter, LinkedIn, Facebook, and YouTube are included in this document as inactive textual references only.
Media / Investor Contacts
Louise Day, Volition
+44 (0)7557 774620
Scott Powell, Volition
+1 (646) 650 1351
Joseph Green, Edison Advisors
+1 (646) 653 7030
NucleosomicsTM and Nu.QTM and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries.
SOURCE VolitionRx Ltd
Released March 25, 2019